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Abstract
According	to	the	World	Health	Organization,	cardiovascular	diseases	are	the	leading	
cause	of	death	in	the	world.	Therefore,	early	prevention	of	these	diseases	is	a	pub-
lic	health	priority.	Epidemiological	data	suggest	that	 insomnia	may	be	a	modifiable	
risk	factor	for	cardiovascular	diseases.	A	randomized	controlled	trial	in	a	sample	of	
insomnia patients without cardiovascular disease was conducted to investigate the 
effects of insomnia treatment on early markers of cardiovascular diseases assessed 
by	24-hr	ambulatory	blood	pressure,	heart	rate	and	heart	rate	variability	monitoring,	
and	morning	fasting	blood	samples.	Forty-six	patients	with	insomnia	disorder	were	
randomized	to	cognitive	behavioural	therapy	for	insomnia	(CBT-I;	n = 23) or a waitlist 
control condition (n	=	23).	Contrary	to	the	hypothesis,	intention-to-treat	analyses	did	
not show any significant treatment effects on early markers of cardiovascular disease 
(d = 0.0–0.6) despite successful insomnia treatment (d = 1.3). Potential methodologi-
cal	and	conceptual	reasons	for	these	negative	findings	are	discussed.	Future	studies	
might	include	larger	sample	sizes	that	are	at	risk	of	cardiovascular	diseases	and	focus	
on other cardiovascular markers.
K E Y W O R D S
cardiovascular	risk,	CBT-I,	insomnia
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1  | INTRODUC TION
According	 to	 the	 World	 Health	 Organization,	 cardiovascular	 dis-
eases are the leading cause of death in the world (World Health 
Organization,	 2016).	 Thus,	 early	 prevention	 of	 these	 diseases	 and	
the identification of modifiable risk factors are public health priori-
ties potentially affecting millions of people worldwide.
Insomnia,	 defined	 by	 difficulties	 initiating	 and/or	 maintaining	
sleep	and	daytime	consequences,	might	be	an	important	but	hitherto	
neglected	 risk	 factor	 for	 cardiovascular	diseases.	Although	 insom-
nia	 is	often	viewed	as	a	nuisance	symptom,	 there	 is	meta-analytic	
evidence from longitudinal epidemiological cohort studies showing 
that	those	with	night-time	insomnia	symptoms	have	a	1.3–1.6	times	
higher risk of developing cardiovascular diseases than those without 
insomnia	(Li,	Zhang,	Hou,	&	Tang,	2014;	Sofi	et	al.,	2014).	Whether	
this	association	can	be	attributed	to	confounding	factors,	especially	
to	sleep	apnea,	is	an	open	question;	however,	there	is	also	some	ev-
idence	suggesting	that	this	might	not	be	the	case	(Fan	et	al.,	2019).	
In	 addition	 to	 these	 epidemiological	 data,	 there	 is	 evidence	 from	
Mendelian	randomization	analyses	in	large	samples	suggesting	that	
the link between insomnia and cardiovascular diseases might be 
causal	 in	nature	(Jansen	et	al.,	2019;	Lane	et	al.,	2019).	This	would	
have very important healthcare implications because only in the 
case	of	a	 true	causal	 relationship,	 can	 the	successful	 treatment	of	
insomnia be assumed to reduce the risk of cardiovascular diseases.
For	 ethical	 reasons,	 it	 appears	 to	 be	 inappropriate	 to	 conduct	
randomized	 controlled	 trials	 comparing	 standard	 insomnia	 treat-
ment	with	a	non-treated	control	group	to	investigate	the	long-term	
impact	on	 the	 incidence	of	 cardiovascular	diseases.	However,	 it	 is	
possible to investigate the effects of insomnia treatment on early 
markers	 of	 cardiovascular	 disease	 such	 as	 blood	 pressure	 (Law,	
Morris,	 &	 Wald,	 2009),	 heart	 rate	 (Jouven	 et	 al.,	 2005;	 Zhang,	
Shen,	 &	 Qi,	 2016),	 heart	 rate	 variability	 (Lahiri,	 Kannankeril,	 &	
Goldberger,	2008)	or	blood	sample	parameters	 (C-reactive	protein	
[CRP]	 (Danesh	 et	 al.,	 2004);	 n-terminal	 pro-brain	 natriuretic	 pep-
tide	 [NT-proBNP]	 (Geng,	 Huang,	 Song,	 &	 Song,	 2017);	 cystatin	 C	
(van	 der	 Laan	 et	 al.,	 2016)).	 This	 approach	 has	 been	 adopted	 in	 a	
few	clinical	 trials,	but	with	mixed	outcomes.	McGrath	et	al.	 (2017)	
did not find any effects of an online insomnia intervention on sys-
tolic	blood	pressure	as	measured	by	a	24-hr	ambulatory	blood	pres-
sure assessment. Jarrin et al. (2016) found that sleep improvements 
after	insomnia	treatment	(CBT-I)	correlated	with	measures	of	heart	
rate	variability	 in	an	uncontrolled	study.	However,	 contrary	 to	 the	
hypothesis,	 treatment-related	 improvements	 in	 sleep	 parameters	
were associated with a reduction in parasympathetic activation and 
an	increase	in	sympathovagal	balance,	indicating	rather	an	adverse	
effect	of	CBT-I	on	heart	rate	variability.	Irwin	et	al.	(2014)	reported	
a	significant	reduction	of	C-reactive	protein	(CRP)	levels	16	months	
after	CBT-I	in	a	randomized	controlled	trial.	In	general,	early	markers	
of cardiovascular diseases were only secondary outcomes in two of 
these	 three	studies	 (Irwin	et	al.,	2014;	 Jarrin	et	al.,	2016),	and	 the	
hypertension	 trial,	 although	 methodologically	 rigorous,	 reported	
comparably	small	effects	of	the	insomnia	treatment	on	sleep-related	
outcomes,	 thus	reducing	the	 likelihood	of	 finding	significant	 treat-
ment	effects	on	blood	pressure	(McGrath	et	al.,	2017).
The current study was specifically designed to evaluate the 
effects of insomnia treatment on early markers of cardiovascular 
diseases.	A	randomized	controlled	trial	was	carried	out	to	test	the	ef-
fects	of	cognitive	behavioural	therapy	for	insomnia	(CBT-I),	the	first-
line	 treatment	 for	 insomnia	 (Qaseem,	 Kansagara,	 Forciea,	 Cooke,	
&	Denberg,	2016;	Riemann	et	al.,	2017),	on	several	cardiovascular	
markers.	To	minimize	the	potential	effect	of	confounding	comorbid-
ities	on	 trial	outcomes,	only	patients	with	 insomnia	disorder	with-
out	comorbid	health	conditions	were	recruited	(Morin	et	al.,	2015;	
Riemann	et	al.,	2015).	The	primary	hypothesis	was	that	CBT-I	would	
lead to a significant reduction of the average systolic blood pressure 
as	measured	 by	 24-hr	 ambulatory	 assessments	 at	 post-treatment.	
Systolic blood pressure has been selected as a primary outcome be-
cause	of	its	reliable	association	with	both	insomnia	(Meng,	Zheng,	&	
Hui,	2013)	and	cardiovascular	diseases	(Law	et	al.,	2009).	Secondary	
outcomes	included	the	average	24-hr	diastolic	blood	pressure,	night-
time	 and	 daytime	 blood	 pressure	measures,	 24-hr,	 night-time	 and	
daytime	 heart	 rate	 and	 heart	 rate	 variability	measures,	 as	well	 as	
early	cardiovascular	markers	from	blood	samples	(CRP,	NT-proBNP	
and	cystatin	C).	As	several	authors	reported	that	only	insomnia	with	
objective short sleep duration is associated with cardiovascular out-
comes	 (Bathgate,	Edinger,	Wyatt,	&	Krystal,	2016;	Vgontzas,	Liao,	
Bixler,	Chrousos,	&	Vela-Bueno,	 2009),	 exploratory	 analyses	were	
carried	 out	 to	 investigate	 treatment	 effects	 in	 this	 subgroup,	 al-
though these analyses did not form part of the initial study design.
2  | MATERIAL AND METHODS
2.1 | Procedure
The	 study	 flow	 chart	 of	 the	 randomized	 clinical	 trial	 is	 presented	
in	Figure	1.	The	 screening	procedure	 involved	a	 clinical	 interview	
and physical examination by an experienced psychiatrist special-
ized	 in	 sleep	medicine,	 two	nights	of	polysomnography	 in	 a	 sleep	
laboratory,	and	a	blood	 test	 (blood	cell	 count,	and	 liver,	 renal	and	
thyroid functioning) that was collected in the morning after the 
first	sleep	laboratory	night.	Afterwards,	all	patients	completed	the	
baseline	assessments	(T0),	which	first	included	a	24-hr	ambulatory	
blood	 pressure,	 heart	 rate	 and	 heart	 rate	 variability	 monitoring,	
morning fasting blood and urine samples of early markers of cardio-
vascular	diseases,	and	then	a	1-week	sleep	diary	and	the	following	
questionnaires:	the	Insomnia	Severity	Index	(ISI;	Bastien,	Vallières,	
&	 Morin,	 2001),	 Pittsburgh	 Sleep	 Quality	 Index	 (PSQI;	 Buysse,	
Reynolds,	 Monk,	 Berman,	 &	 Kupfer,	 1989),	 Multidimensional	
Fatigue	Inventory	(MFI;	Smets,	Garssen,	Bonke,	&	de	Haes,	1995),	
Epworth	 Sleepiness	 Scale	 (ESS;	 Johns,	 1991),	 Glasgow	 Sleep	
Effort	Scale	(GSES;	Broomfield	&	Espie,	2005),	brief	version	of	the	
Dysfunctional	 Beliefs	 and	Attitudes	 about	 Sleep	 Scale	 (DBAS-16;	
Morin,	 Vallières,	 &	 Ivers,	 2007),	 Pre-Sleep	 Arousal	 Scale	 (PSAS;	
Nicassio,	 Mendlowitz,	 Fussell,	 &	 Petras,	 1985),	 Beck	 Depression	
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Inventory	 (BDI;	Beck,	Ward,	Mendelson,	Mock,	&	Erbaugh,	1961),	
State	Trait	Anxiety	Inventory	(STAI;	Spielberger,	Gorsuch,	Lushene,	
Vagg,	 &	 Jacobs,	 1983),	 Medical	 Outcomes	 Study	 36-item	 short-
form	 health	 survey	 36	 (SF-36;	 Ware	 &	 Sherbourne,	 1992),	 and	
Frost	Multidimensional	Perfectionism	Scale	 (FMPS;	Frost,	Marten,	
Lahart,	&	Rosenblate,	1990).	After	completion	of	T0,	patients	were	
randomized	 using	 age-,	 gender-	 and	 ISI-stratified	 randomization.	
Patients were first assigned to one of eight possible combinations 
of	covariates	(lower	vs.	higher	age,	men	vs.	women,	lower	vs.	higher	
ISI	scores).	Simple	randomization	was	then	performed	within	each	
block	 using	 sealed	 opaque	 envelopes.	 The	 post-treatment/post-
waiting list assessment (T1) was conducted as soon as possible after 
the	completion	of	the	treatment/the	8-week	waiting	list	condition,	
including	the	same	measurements	as	at	T0	 in	 the	same	order.	For	
ethical	reasons,	patients	in	the	waiting	list	control	condition	received	
CBT-I	after	T1.	Thus,	no	follow-up	data	were	collected.	Non-abusive	
use of caffeine and alcohol was allowed during study participation.
2.2 | Participants
Between	 March	 2015	 and	 July	 2017,	 46	 patients	 diagnosed	 with	
insomnia	 disorder	 according	 to	 DSM-5	 criteria	 participated	 in	 this	
study.	All	patients	were	referred	to	the	outpatient	sleep	clinic	at	the	
F I G U R E  1  Study	flow	chart	of	the	randomized	controlled	trial
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Department	of	Psychiatry	and	Psychotherapy	at	the	Medical	Center	
–	University	of	Freiburg,	Germany,	by	a	medical	specialist	or	primary	
care	provider.	 In	our	 sleep	 clinic,	 the	diagnosis	of	 insomnia	disorder	
was	 made	 by	 a	 board-certified	 psychiatrist	 with	 a	 specialization	 in	
sleep	medicine.	Only	patients	with	an	age	between	18	and	65	years	
were	included.	Exclusion	criteria	were	any	other	comorbid	psychiatric	
or	sleep	disorder,	intake	of	medication	affecting	sleep	in	the	2	weeks	
before	or	during	study	participation	(stable	long-term	antihypertensive	
or thyroid medication was allowed if the patient's medical history did 
not	suggest	clinically	significant	effects	on	sleep),	a	sleep	apnea	index	
>5/hr,	a	periodic	leg	movements	during	sleep	with	arousal	index	>5/hr,	
night	shift	work,	suicidality,	previous	treatment	with	CBT-I,	heart	fail-
ure	NYHA	II-IV,	heart	transplants,	acute	infectious	diseases,	end-stage	
renal disease and cancer. The study was conducted in accordance with 
the Declaration of Helsinki and was registered in the German Clinical 
Trials	 Register	 (https://www.drks.de/drks_web/;	 DRKS00007128).	
The	study	protocol	was	approved	by	the	Institutional	Review	Board	of	
the	University	Medical	Centre	Freiburg.	Written	informed	consent	was	
obtained from all patients prior to any examination.
2.3 | Polysomnography
As	 part	 of	 the	 screening	 procedure,	 all	 patients	 underwent	 two	
consecutive nights of polysomnography (PSG) sleep monitoring. On 
the days prior to these nights they had to refrain from caffeine and 
alcohol.	Sleep	was	recorded	for	8	hr	 from	22:09	hr	±	20	min	until	
6:09	hr	±	20	min	adjusted	to	individual	habitual	bedtimes.	The	first	
night was used as an adaptation and screening night and the sec-
ond	 night	 for	 the	 assessment	 of	 sleep	 parameters.	 All	 recordings	
included	 electroencephalogram	 (EEG)	 (C3-A2;	 C4-A1),	 electro-
oculography	 (EOG)	 (horizontal	and	vertical)	 and	electromyography	
(EMG)	 (submental)	and	were	scored	visually	by	experienced	raters	
according	to	the	American	Academy	of	Sleep	Medicine	(AASM)	cri-
teria	(Silber	et	al.,	2007).	All	patients	were	screened	for	apneas	and	
periodic leg movements by monitoring abdominal and thoracic ef-
fort,	nasal	airflow,	oximetry,	and	bilateral	tibialis	anterior	EMG.	Sleep	
recordings were evaluated for the following parameters: total sleep 
time	(TST);	sleep	onset	latency,	defined	as	time	from	lights	out	until	
sleep onset (defined as the first epoch of stage 2); wake after sleep 
onset	(WASO),	defined	as	the	difference	between	sleep	period	time	
(SPT; time from sleep onset until final awakening) and TST; number 
of awakenings; sleep efficiency (ratio of TST to time in bed); arousal 
index (per hour); sleep apnea index (per hour); periodic leg move-
ments	 during	 sleep	with	 arousal	 index	 (per	 hour);	 and	 stages	 1,	 2	
and	slow	wave	sleep	(SWS)	and	rapid	eye	movement	sleep	(REM)	as	
percentages of SPT.
2.4 | Blood pressure
Ambulatory	24-hr	systolic	and	diastolic	blood	pressure	were	meas-
ured	 at	 T0	 and	 T1	 on	 a	 working	 day	 using	 the	 custo	 screen	 400	
device	 (custo	 med	 GmbH;	 https://www.custo	med.de/),	 includ-
ing	 a	 blood	 pressure	 cuff,	 a	 Holter	 Ambulatory	 Blood	 Pressure	
Measurement	(ABPM)	recorder	and	a	three-electrode	ECG	transmit-
ter with an electrode belt placed around the chest according to the 
manufacturer’s	 recommendations.	 Recordings	 started	 and	 ended	
at	 20:00	hours,	with	 hourly	 blood	pressure	 assessments	 between	
22:00	 and	 06:00	 hours	 (night-time)	 and	 half-hourly	 assessments	
before and after this period (daytime). Patients were instructed to 
remove	 the	 device	 for	 showering	 and	 exercise,	 and	missing	 blood	
pressure	data	for	the	hourly	and	half-hourly	time	slots	were	imputed	
by	averaging	neighbouring	non-missing	data	points.	All	blood	pres-
sure data were inspected visually for artefacts or outliers but none 
were identified.
2.5 | Heart rate and heart rate variability
Epochs	 of	 30	 s	 length	were	 extracted	 from	 the	 ECG	 to	 analyse	
heart	rate	and	heart	rate	variability.	After	applying	a	high-pass	fil-
ter	at	4.5	Hz,	a	peak	detection	algorithm	was	used	to	identify	QRS	
complexes. Occasional ectopic beats were automatically identi-
fied and replaced with the linearly interpolated RR interval (RRI) 
data.	 Epochs	with	 body	movements	 or	 accumulated	 artefacts	 of	
more	 than	10	s	were	discarded	 from	the	analysis.	For	evaluating	
heart	 rate	 variability,	 both	 time	 and	 frequency	 domain	methods	
were	applied.	 In	the	time	domain,	 the	standard	deviation	of	RRIs	
(SDNN)	was	computed	for	each	epoch,	reflecting	overall	heart	rate	
variability.	Frequency	domain	measures	based	on	the	fast	Fourier	
transform	(FFT)	algorithm	were	applied	on	the	RRI	time	series	re-
sampled	 to	 a	 regular	 sampling	 rate	 of	 1	Hz.	 The	whole	RRI	 time	
series	 was	 filtered	 in	 two	 frequency	 bands:	 low	 frequency	 (LF;	
0.04–0.15	Hz)	 and	 high	 frequency	 (HF;	 0.15–0.4	 Hz)	 using	 FFT.	
Subsequently,	mean	 absolute	 values	were	 computed	 for	 succes-
sive	30-s	epochs.	The	LF/HF	ratio	was	computed	as	a	marker	for	
sympathovagal	balance.	Epoch-wise	heart	rate,	LF/HF	and	SDNN	
data were inspected visually for artefacts or outliers but none 
were identified.
2.6 | Blood sample
A	routine	fasting	blood	sample	was	taken	in	the	morning	at	T0	and	
T1.	 CRP,	 NT-proBNP	 and	 cystatin	 C	 levels	 were	 determined	 by	
the	Institute	of	Clinical	Chemistry	and	Laboratory	Medicine	of	the	
Medical	Center	–	University	of	Freiburg,	Germany,	within	the	clinical	
routine.	NT-proBNP	levels	below	50	pg/ml	are	not	precisely	deter-
mined	within	this	clinical	routine	and	were,	thus,	set	to	50	pg/ml.
2.7 | Cognitive behavioural therapy for insomnia
The	CBT-I	intervention	was	provided	by	the	first	(12	patients)	and	
last authors (11 patients) and consisted of eight weekly individual 
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sessions lasting 50 min each. The treatment comprised sleep hy-
giene	 education,	 relaxation	 training,	 sleep	 restriction	 therapy,	
stimulus control therapy and cognitive therapy. Sleep hygiene ed-
ucation	involved	general	information	about	sleep	and	insomnia,	in-
cluding	the	so-called	“sleep	hygiene	rules”	about	health	practices	
(e.g.,	exercise,	caffeine	and	alcohol	use)	and	environmental	factors	
(e.g.,	 light,	noise	and	temperature)	that	may	promote	or	interfere	
with sleep. Relaxation therapy included progressive muscle relaxa-
tion and autogenic training. Sleep restriction therapy was based 
on continuous sleep diary data. The initial sleep window was gen-
erated	using	the	average	total	sleep	time	of	7	days	of	sleep	diary	
data. The window was positioned according to patient preference. 
The	minimum	time	in	bed	was	4	hr.	On	a	weekly	basis,	time	in	bed	
was either increased by 30 min when sleep efficiency was >90% 
or	decreased	by	30	min	when	sleep	efficiency	was	<80%	and	re-
mained	the	same	when	sleep	efficiency	was	80%–90%.	Stimulus	
control	therapy	was	used	as	described	in	Bootzin	(1972).	Cognitive	
elements	included	cognitive	restructuring,	constructive	worry	and	
paradoxical intention.
2.8 | Statistical analysis
All	 analyses	 were	 carried	 out	 using	 the	 statistical	 software	 pack-
age	 R	 (http://www.R-proje	ct.org/).	 Descriptive	 presentation	 of	
the data includes mean values and standard deviations. Data were 
analysed	 using	 an	 intention-to-treat	 approach.	Missing	 data	 at	 T1	
were	 imputed	 using	 the	 last-observation-carried-forward	method.	
Treatment	effects	were	analysed	using	two-way	ANOVAs	with	the	
between-subject	factor	group	(treatment	vs.	waiting	list),	the	within-
subject	factor	time	(T0	vs.	T1),	and	the	group	×	time	interaction.	The	
primary	outcome	was	the	mean	24-hr	systolic	blood	pressure.	The	
level of significance was set at p	<	.05	(two-tailed).	Exploratory	anal-
yses were carried out to investigate treatment effects in those with 
objective short sleep duration. To be consistent with the data from 
the	Penn	State	Cohort	 (e.g.,	Vgontzas	 et	 al.,	 2009),	 insomnia	with	
objective short duration was defined as a polysomnographically de-
termined total sleep time of <6 hr on the first sleep laboratory night. 
For	 the	 exploratory	 analyses,	 insomnia	 patients	without	 objective	
short sleep duration were removed from the treatment group and 
the same analyses were conducted as described above for the pri-
mary analyses.
3  | RESULTS
3.1 | Sample characteristics and treatment efficacy
The	study	sample	 included	46	patients	with	 insomnia	disorder	 (29	
women,	17	men;	CBT-I	group:	14	women,	9	men;	waiting	list	control	
group:	15	women,	8	men)	with	an	age	of	41.0	±	14.5	years	 (CBT-I	
group:	40.8	±	14.0	years;	waiting	list	control	group:	41.2	±	15.1	years).	
Missing	data	at	T1	was	imputed	for	two	patients	of	the	waiting	list	
control group who could not be assessed at T1 as they were admit-
ted to hospital. One patient had an accident not related to daytime 
fatigue/tiredness and the other patient suffered from severe back 
pain involving intake of analgesic medication.
Polysomnographic data of the sample are presented in Table 1 
and	 Table	 S1.	 Eleven	 patients	 in	 the	 CBT-I	 group	 were	 assigned	
to	 the	group	with	objective	 short	 sleep	duration.	On	average,	 the	
patients	 in	 the	CBT-I	group	attended	7.3	±	1.3	 treatment	sessions	
in	8.9	±	3.0	weeks;	 the	average	duration	between	T0	and	T1	was	
12.7	±	4.8	weeks.	T0	and	T1	data	for	subjective	sleep-related	and	
psychopathology-related	 outcomes	 are	 presented	 in	 Table	 2	 and	
Table	S2,	illustrating	a	high	treatment	efficacy	(d	=	−1.3)	comparable	
to	meta-analytical	 data	of	CBT-I	 effects	 (Ballesio	 et	 al.,	 2018;	 van	
Straten	et	al.,	2018).
3.2 | Blood pressure
Blood	pressure	data	are	presented	in	Table	3.	There	was	no	signifi-
cant	group	×	time	interaction	effect	for	mean	24-hr	systolic	or	dias-
tolic	blood	pressure.	Likewise,	there	was	no	significant	group	×	time	
interaction	effect	on	night-time	systolic	or	diastolic	blood	pressure	
or	on	daytime	 systolic	or	diastolic	blood	pressure.	 In	 addition,	 ex-
ploratory correlational analyses did not show any significant asso-
ciations	between	 improvement	 in	 ISI	 scores	and	changes	 in	24-hr,	
night-time	or	daytime	systolic	or	diastolic	blood	pressure	levels	be-
tween T0 and T1 (all p > .2). This pattern of results suggests that 
CBT-I,	at	a	dose	effective	for	insomnia,	had	no	detectable	effects	on	
blood	pressure.	Figure	2	presents	group	data	for	each	time	slot.	The	
TA B L E  1  Baseline	data	(second	night	of	polysomnography)
Variable
Second night, 
treatment group
Second night, waiting 
list control group
TST (min) 397.8	±	40.9 409.8	±	34.6
SOL	(min) 19.9	±	12.0 19.0	±	12.1
WASO	(min) 43.7	±	27.4 45.7	±	29.4
NOA 25.7	±	8.0 26.2	±	6.3
SE	(%) 83.0	±	8.6 85.4	±	7.2
Arousal	index	
(hr−1)
13.7	±	4.7 15.5	±	6.8
Apnea	index	
(hr−1)
0.4	±	0.5 0.2	±	0.6
PLMS	index	(hr−1) 0.7	±	1.7 0.5	±	0.8
Stage 1 (% SPT) 7.9	±	3.3 7.5	±	3.2
Stage 2 (% SPT) 53.3	±	8.4 54.7	±	7.0
SWS (% SPT) 10.6	±	8.1 9.8	±	8.3
REM	(%	SPT) 18.3	±	5.4 18.0	±	4.9
Note: Results	depict	means	±	standard	deviations.
Abbreviations:	NOA,	number	of	awakenings;	PLMS,	periodic	leg	
movements	during	sleep;	REM,	rapid	eye	movement	sleep;	SE,	sleep	
efficacy;	SOL,	sleep	onset	latency;	SPT,	sleep	period	time;	SWS,	slow	
wave	sleep;	TST,	total	sleep	time;	WASO,	wake	after	sleep	onset.
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exploratory analyses for treatment effects in those with objective 
short	sleep	duration	also	did	not	show	any	significant	group	×	time	
interaction	 effect	 for	 24-hr,	 night-time	 or	 daytime	 diastolic	 blood	
pressure (all p > .1).
3.3 | Heart rate and heart rate variability
One patient in the treatment group had to be excluded from the 
heart rate and heart rate variability analysis. The patient took off the 
electrocardiography belt early in the evening at T0 and refused to 
wear	it	again	at	T1.	For	three	additional	patients,	two	of	whom	were	
in	 the	 treatment	 group	 and	one	 in	 the	 control	 group,	 the	 last-ob-
servation-carried-forward	method	had	to	be	used	because	of	device	
handling errors or technical problems with the electrocardiography 
belt at T1. Heart rate and heart rate variability data are presented in 
Table	4.	There	was	no	significant	group	×	time	interaction	effect	for	
mean	24-hr	heart	rate,	LF/HF	or	SDNN.	Likewise,	there	were	no	sig-
nificant	group	×	time	interaction	effects	on	night-time	heart	rate,	LF/
HF	or	SDNN	or	on	daytime	heart	rate,	LF/HF	or	SDNN.	In	addition,	
exploratory correlational analyses did not show any significant as-
sociations	between	improvement	in	ISI	scores	and	changes	in	24-hr,	
night-time	or	daytime	HR,	LF/HF	or	SDNN	between	T0	and	T1	(all	
p	>	.2).	This	pattern	of	results	suggests	that	CBT-I	had	no	detectable	
effects on heart rate and heart rate variability in this sample. The 
exploratory analyses for treatment effects in those with objective 
short	sleep	duration	also	did	not	show	any	significant	group	×	time	
interaction	effect	for	24-hr,	night-time	or	daytime	heart	rate,	LF/HF	
or SDNN (all p > .1).
3.4 | Blood test
Due	to	errors	in	blood	sampling	and	analysis,	there	were	two	missing	
datasets	for	CRP	at	T0.	These	two	patients,	who	both	formed	part	
of	the	intervention	group,	were	excluded	from	the	analysis.	In	addi-
tion,	the	last-observation-carried-forward	method	was	used	for	one	
patient	 in	the	control	group	with	missing	data	at	T1,	as	well	as	for	
two patients in the intervention group and one patient in the control 
group	with	CRP	 levels	>10	mg/L	at	T1.	CRP	data	are	presented	 in	
Table	5.	There	was	no	significant	group	×	time	interaction	effect	on	
CRP levels and no significant correlation between improvement in 
ISI scores and changes in CRP levels between T0 and T1 (r	=	−.06;	
p	=	.722).
TA B L E  2   Psychometric data
Questionnaire
Treatment Control Treatment × Time Effect size
Pre Post Pre Post F p d
ISI 15.4	±	4.3 6.5	±	3.8 14.5	±	5.0 13.0	±	4.7 35.51 .000 −1.3
SD-TST	(hr) 5.9	±	1.4 6.3	±	1.4 5.7	±	1.1 6.2	±	1.3 0.10 .757 −0.1
SD-TIB	(hr) 8.1	±	0.9 7.1	±	1.1 7.9	±	0.8 8.0	±	0.9 8.98 .005 −0.8
MFI 50.1	±	11.4 39.1	±	11.5 55.3	±	14.7 53.1	±	18.0 7.86 .007 −0.8
BDI 6.5	±	5.4 3.2	±	4.0 9.7	±	4.3 8.8	±	5.0 4.58 .038 −0.6
STAI	(state) 37.9	±	7.9 32.6	±	7.9 43.4	±	10.0 41.3	±	10.6 2.09 .155 −0.4
STAI	(trait) 39.5	±	8.0 34.0	±	8.2 43.5	±	8.6 42.1	±	9.2 6.34 .016 –0.4
Note: Results	depict	means	±	standard	deviations.
Abbreviations:	BDI,	Beck	Depression	Inventory;	ISI,	Insomnia	Severity	Index;	MFI,	Multidimensional	Fatigue	Inventory;	SD-TIB,	sleep	diary	–	time	in	
bed;	SD-TST,	sleep	diary	–	total	sleep	time;	STAI	(state),	State-Trait	Anxiety	Inventory	(state);	STAI	(trait),	State-Trait	Anxiety	Inventory	(trait).
TA B L E  3  Blood	pressure	data	(mm	Hg)
Variable
Treatment Control Treatment × Time Effect size
Pre Post Pre Post F p D
Mean	24-hr	systolic	blood	pressure 124	±	11 124	±	13 126	±	11 125	±	11 0.20 .654 0.1
Mean	24-hr	diastolic	blood	pressure 83	±	7 83	±	9 84	±	5 83	±	7 0.99 .325 0.3
Night-time	systolic	blood	pressure 113	±	12 113	±	13 115	±	13 116	±	13 0.13 .725 0.1
Night-time	diastolic	blood	pressure 74	±	8 73	±	8 75	±	7 75	±	8 0.04 .846 –0.1
Daytime systolic blood pressure 127	±	12 127	±	14 129	±	11 128	±	12 0.36 .553 0.2
Daytime diastolic blood pressure 85	±	8 85	±	9 87	±	5 85	±	8 1.10 .301 0.3
Note: Results	depict	means	±	standard	deviations.
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There	was	one	missing	dataset	 for	NT-proBNP	at	 T0,	 and	 this	
patient	was	excluded	from	the	intervention	group.	The	last-observa-
tion-carried-forward	method	was	used	for	one	patient	from	the	con-
trol	group	with	missing	data	at	T1.	NT-proBNP	data	are	presented	in	
Table	5.	There	was	no	significant	group	×	time	interaction	effect	on	
NT-proBNP	levels	and	no	significant	correlation	between	improve-
ment	in	ISI	scores	and	changes	in	NT-proBNP	levels	between	T0	and	
T1 (r	=	−.18;	p = .239).
There	were	two	missing	datasets	for	cystatin	C	at	T0,	one	in	the	
intervention	group	and	one	in	the	control	group,	and	these	patients	
were	 excluded.	 The	 last-observation-carried-forward	method	 was	
used for one additional patient in the control group with missing 
data at T1. Cystatin C data are presented in Table 5. There was no 
significant	group	×	time	interaction	effect	on	cystatin	C	levels	and	
no significant correlation between improvement in ISI scores and 
changes in cystatin C levels between T0 and T1 (r	=	−.06;	p	=	.723).
This	pattern	of	results	suggests	that	CBT-I	had	no	detectable	ef-
fects on blood sample parameters in this sample. The exploratory 
analysis for treatment effects in those with objective short sleep 
duration	also	did	not	show	any	significant	group	×	time	interaction	
effect	for	CRP,	NT-proBNP	and	cystatin	C	levels	(p > .1).
4  | DISCUSSION
In	the	current	study	sample,	no	evidence	could	be	found	in	support	
of	the	idea	that	CBT-I	has	an	effect	on	early	markers	of	cardiovas-
cular	disease,	that	is,	systolic	and	diastolic	blood	pressure,	heart	rate	
and	heart	 rate	variability	measures,	CRP,	NT-proBNP	and	cystatin	
C,	in	patients	with	insomnia	disorder.	The	data	on	insomnia	severity	
show that this result emerged despite successful insomnia treatment 
with	an	ISI	reduction	of	8.9	points	in	the	treatment	group	compared	
to	1.5	points	in	the	waiting	list	control	group.	Therefore,	it	appears	
rather unlikely that the absence of a group by time effect on early 
markers of cardiovascular disease can be attributed to an ineffective 
therapeutic intervention.
There are a number of potential reasons for these negative find-
ings.	First,	the	study	did	not	focus	on	individuals	at	risk	of	cardiovas-
cular disease or individuals with pathological levels of early markers 
for	 cardiovascular	disease	 (e.g.,	 patients	with	hypertension	or	ele-
vated CRP levels). These individuals might have had a greater poten-
tial	for	improvement	in	early	markers	of	cardiovascular	disease,	and	
thus,	the	current	study	might	have	been	limited	by	floor	and	ceiling	
effects.	 However,	 in	 principle,	 markers	 of	 cardiovascular	 disease	
can	be	changed	even	when	they	are	in	the	normal	range,	at	least	by	
pharmacological	 agents	 (Thomopoulos,	 Parati,	&	Zanchetti,	 2017).	
To	the	best	of	our	knowledge,	there	is	no	evidence	suggesting	that	
non-pharmacological	 interventions	show	a	fundamentally	different	
pattern	of	results	(e.g.,	with	positive	effects	on	increased	blood	pres-
sure and no effect on normal or decreased blood pressure).
Second,	it	is	conceivable	that	potential	cardioprotective	effects	
of	 CBT-I	manifest	 themselves	 only	 in	 the	 long	 term,	 and	 that	 our	
study was not able to detect these effects because of a lack of fol-
low-up	assessment.	Our	study,	however,	was	designed	to	investigate	
short-term	effects	of	CBT-I	on	early	markers	of	cardiovascular	dis-
ease	for	the	ethical	reasons	described	above.	Although	most	studies	
report	that	CBT-I	effects	on	subjective	sleep-related	outcomes	are	
simply	sustained	at	follow-up	assessments	(Morin,	Colecchi,	Stone,	
Sood,	 &	 Brink,	 1999),	 knowledge	 on	 the	 time	 course	 of	 psycho-
therapy	 effects	 on	 physiological	 outcomes	 is	 very	 limited	 (Abbott	
et	al.,	2014;	Gonçalves	et	al.,	2015).
Third,	in	the	current	study,	patients	with	insomnia	were	selected	
without	reference	to	objective	sleep	parameters.	Although	this	is	in	
line with diagnostic criteria and improves the ecologic validity of our 
results,	considerable	evidence	suggests	 that	polysomnographically	
determined short sleep duration may be a marker of biologic severity 
F I G U R E  2   Group data for systolic (top) and diastolic (bottom) 
blood pressure for each time slot
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of	 insomnia	 (Vgontzas,	 Fernandez-Mendoza,	 Liao,	 &	 Bixler,	 2013)	
and	 related	 to	 hypertension	 (Vgontzas	 et	 al.,	 2009,	 2013),	 heart	
rate	variability	 (Spiegelhalder	et	al.,	2011)	and	 inflammatory	mark-
ers	(Fernandez-Mendoza	et	al.,	2017).	Against	this	background,	it	is	
conceivable that successful insomnia treatment might have a more 
pronounced effect on early markers of cardiovascular disease in in-
somnia patients with objective short sleep duration. This idea did 
not form part of the initial set of hypotheses as laid out in the study 
design,	but	was	also	pursued.	Yet,	 additional	 exploratory	 analyses	
did	 not	 support	 this	 idea.	 However,	 because	 the	 sample	 size	 for	
these	analyses	was	small,	 future	 investigations	should	explore	this	
with	greater	statistical	power.	In	this	context,	it	has	to	be	admitted	
that a polysomnographic assessment at T1 would have been infor-
mative for a more complete evaluation of the effects of objective 
short sleep duration on early markers of cardiovascular disease.
Fourth,	 both	 at	 T0	 and	 T1,	 polysomnographic	 recordings	
during	 the	 24-hr	 blood	 pressure,	 heart	 rate	 and	 heart	 rate	 vari-
ability assessments would have helped to evaluate whether a po-
tential	treatment	effect	on	the	night-time	parameters	might	have	
been	compromised	by	a	pre-	to	post-treatment	reduction	in	total	
sleep	time	in	the	CBT-I	group	due	to	sleep	restriction	or	stimulus	
control	therapy.	Put	differently,	it	is	also	conceivable	that	possible	
negative cardiovascular effects due to sleep restriction therapy 
mask	potentially	positive	effects	of	behavioural	therapy,	resulting	
in	 a	 non-significant	 change	 in	 cardiovascular	 outcome	 parame-
ters.	 Indeed,	 objective	 sleep	 duration	 appears	 to	 be	moderately	
reduced	 following	 CBT-I	 (Mitchell,	 Bisdounis,	 Ballesio,	 Omlin,	 &	
Kyle,	2019).	Thus,	if	objective	sleep	duration	is	a	major	factor	link-
ing	insomnia	to	cardiovascular	disease,	CBT-I	may	fail	to	improve	
early markers of cardiovascular disease because of a lack of posi-
tive effects on objective sleep duration.
Fifth,	the	sample	size	of	the	current	study	needs	to	be	discussed.	
The a-priori	power	analysis	was	based	on	the	assumption	that	CBT-I	
has	the	potential	to	produce	medium-sized	effects	on	early	mark-
ers	of	cardiovascular	disease	(ANOVA	within-between	interaction;	
effect	size	f = 0.25; α	=	0.05;	1	−	β = 0.90; correlation among re-
peated measures r = .5). This was based on the observation that 
case–control studies in highly selected samples have reported me-
dium-sized	differences	in	physiological	measures	between	patients	
with	insomnia	and	healthy	controls	(Spiegelhalder	et	al.,	2015),	and	
that	medium	effect	sizes	were	reported	for	antihypertensive	drugs	
(Leucht,	Helfer,	Gartlehner,	&	Davis,	2015).	However,	CBT-I	effects	
on	cardiovascular	markers	might	be	considerably	smaller	than	this,	
and our study lacks the power to detect such effects.
Two other limitations of the current investigation have to be ac-
knowledged.	First,	16%	of	the	time	slots	for	blood	pressure	needed	to	
be	interpolated,	4%	of	the	epochs	for	heart	rate	and	heart	rate	vari-
ability	analyses	did	not	contain	valid	data,	and	5%–11%	of	the	blood	
TA B L E  4   Heart rate and heart rate variability
Variable
Treatment Control Treatment × Time Effect size
Pre Post Pre Post F p d
Mean	24-hr	HR	(bpm) 75	±	7 77	±	7 75	±	9 74	±	9 2.88 .097 0.5
Mean	24-hr	LF/HF 2.1	±	0.5 2.1	±	0.5 2.1	±	0.4 2.1	±	0.4 2.01 .163 0.4
Mean	24-hr	SDNN	(ms) 50	±	17 48	±	16 51	±	19 51	±	17 0.65 .425 –0.2
Night-time	HR	(bpm) 64	±	7 66	±	7 65	±	11 65	±	11 0.58 .450 –0.2
Night-time	LF/HF 1.8	±	0.6 1.8	±	0.5 1.7	±	0.5 1.8	±	0.5 0.02 .885 0.0
Night-time	SDNN	(ms) 55	±	22 51	±	22 56	±	27 54	±	20 0.38 .541 –0.2
Daytime HR (bpm) 81	±	8 82	±	8 80	±	10 78	±	9 3.89 .055 0.6
Daytime	LF/HF 2.2	±	0.5 2.3	±	0.6 2.3	±	0.4 2.2	±	0.5 3.31 .076 0.5
Daytime SDNN (ms) 48	±	16 47	±	15 49	±	16 50	±	15 0.47 .496 –0.2
Note: Results	depict	means	±	standard	deviations.
Abbreviations:	HF,	high	frequency;	HR,	heart	rate;	LF,	low	frequency;	SDNN,	standard	deviation	of	RR	intervals.
TA B L E  5  Blood	test
Variable
Treatment Control Treatment × Time
Effect 
size
Pre Post Pre Post F p d
CRP	(mg/L) 1.0	±	1.3 1.4	±	1.6 0.8	±	0.8 1.0	±	0.9 0.47 .496 0.2
NT-proBNP	(pg/ml) 73	±	38 78	±	47 66	±	34 69	±	55 0.07 .798 0.1
Cystatin	C	(mg/L) 0.87	±	0.10 0.85	±	0.09 0.83	±	0.13 0.84	±	0.13 1.64 .207 −0.4
Note: Results	depict	means	±	standard	deviations.
Abbreviations:	CRP,	C-reactive	protein;	NT-proBNP,	N-terminal	pro	brain	natriuretic	peptide.
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samples were missing or invalid. This reduces the statistical power 
of	the	current	analyses.	Second,	we	recruited	only	patients	with	in-
somnia	disorder	without	comorbid	health	conditions.	Although	this	
reduces potential effects of confounding comorbidities on outcome 
parameters,	it	also	reduces	the	generalizability	of	the	results	for	the	
whole	population	of	patients	with	insomnia,	which	often	occurs	co-
morbid	to	other	conditions	(Vgontzas	et	al.,	2009,	2013).
Finally,	our	results	should	be	interpreted	against	the	background	
of	previous	studies,	which	have	investigated	the	effect	of	CBT-I	on	
heart	 rate	variability,	blood	pressure	and	 inflammatory	markers	as	
early markers of cardiovascular disease. Jarrin et al. (2016) found 
that	 treatment-related	 sleep	 improvements	 were	 associated	 with	
a	reduction	 in	parasympathetic	activation,	 indicating	rather	an	ad-
verse	effect	of	CBT-I	on	heart	rate	variability.	According	to	the	au-
thors,	 this	might	 be	 due	 to	 higher	 levels	 of	 stress	 induced	 by	 the	
surrounding of a sleep laboratory during heart rate variability mea-
surements.	 Yet	 our	 study,	 in	which	 patients'	 heart	 rate	 variability	
was	measured	at	home,	a	much	more	naturalistic	setting	than	a	sleep	
laboratory,	found	no	effect	of	CBT-I	on	heart	rate	variability.	In	line	
with	McGrath	et	al.	 (2017),	we	 found	no	effect	of	CBT-I	on	blood	
pressure.	Although	their	results	may	be	at	least	partly	due	to	a	rather	
modest	treatment	effect	of	CBT-I	(ISI	reduction	of	2.8	points	in	the	
treatment	group),	this	is	rather	unlikely	for	our	study	(ISI	reduction	
of	8.9	points	in	the	treatment	group).	This	suggests	that	CBT-I	does	
not appear to have an effect on blood pressure in insomnia patients. 
With	regard	 to	 inflammatory	 risk,	our	 results	confirm	 Irwin	et	al.'s	
(2014)	finding	that	CBT-I	has	no	immediate	effect	on	CRP.	But	Irwin	
et	al.'s	(2014)	study	also	demonstrates	a	long-term	effect	of	CBT-I	on	
CRP.	This	lends	credibility	to	the	hypothesis	that	CBT-I	does	have	a	
positive	effect	on	cardiovascular	risk	factors,	but	only	in	the	longer	
term.	In	light	of	this,	future	studies	investigating	CBT-I	as	a	cardio-
vascular safeguard should apply a longitudinal design.
In	summary,	CBT-I	had	no	significant	impact	on	early	markers	of	
cardiovascular	disease	in	this	randomized	controlled	trial	of	insom-
nia patients without cardiovascular diseases. In light of these pre-
liminary	 findings,	 future	 studies	might	 include	 larger	 sample	 sizes,	
samples	at	risk	of	cardiovascular	diseases,	longer	observational	pe-
riods	 and/or	 other	markers	 of	 cardiovascular	 disease.	 In	 addition,	
other	evidence-based	treatments	for	 insomnia	 (e.g.,	pharmacologi-
cal treatments) might also be investigated for their effects on early 
markers of cardiovascular disease in future trials.
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